ACROBiosystems | 2025 年，阿茲海默症藥物 (Alzheimer’s Disease Drug) 產品開發現狀

Upcoming event

View as Webpage

Alzheimer’s disease (AD) poses a major global health challenge. Despite several anti-Aβ monoclonal antibodies have been approved, more effective and precise treatments are still urgently needed. Recently, Professor Jeffrey Cummings and his team published a comprehensive review, Alzheimer’s Disease Drug Development Pipeline: 2025, analyzing the current landscape of AD drug trials worldwide. The paper highlights key trends in “growth in scale,” “target diversity,” and “technological innovation” in AD drug development.

· Growth in Scale: 138 Drugs in 182 Trials

As of January 2025, the AD therapeutic landscape shows robust expansion, with 138 drug candidates in 182 clinical trials—a marked increase from 2024 levels. The pipeline breakdown reveals:

• Phase III: 48 trials
• Phase II: 86 trials
•  Phase I: 48 trials (85% YOY growth, , signaling intensified early-stage innovation)

Disease-targeted therapies remain dominant at 74%, while novel MOA exploration accelerates, particularly in Phase I.

· Diverse Targets: Aβ and Tau No Longer Dominating

While Aβ and Tau are the primary focal points, new pathways are gaining traction. Other diverse targets include neurotransmitter receptors (22%), neuroinflammation/immune responses (17%), synaptic plasticity (6%), and energy metabolism (6%). Emerging areas like gut-brain axis and epigenetic regulation are also becoming key research focuses.

doi: 10.1002/trc2.70098

Number of AD Drugs by Mechanism of Action at Different Stages

· Innovation in Technology: Biomarkers, Combination Therapy, and Drug Repurposing

57% of trials use biomarkers for inclusion/exclusion, and 27% make them primary endpoints. MRI and PET scans remain widely used, but there is an increasing application of high-sensitivity biomarkers like p-tau217 and the Aβ42/40 ratio for screening and efficacy evaluation. Additionally, the exploration of combination therapies and repurposed drugs is on the rise, improving both efficiency and cost-effectiveness.

· Aneuro: Advancing AD Research

As the brand focused on neuroscience of ACROBiosystems, Aneuro offers cutting-edge solutions, including target proteins, pre-formed fibrils (PFFs), brain organoids, and p-tau antibodies, to accelerate AD research and drug development.

Awards & Certifications